Chugai Pharmaceutical Co., Ltd.
Fiscal Year Ending December 2025 Consolidated Financial Results [IFRS] Supplementary Materials
For the fiscal year ending December 2025, revenue was JPY 1,257.9 billion (YoY +7.5%), operating income was JPY 598.8 billion (YoY +10.5%), and net income was JPY 434.0 billion (YoY +12.1%), achieving growth in both revenue and profits.
Key Figures
- Revenue: JPY 1,257.9 billion (YoY +7.5%)
- Operating Income: JPY 598.8 billion (YoY +10.5%)
- Net Income: JPY 434.0 billion (YoY +12.1%)
AI要約
Overview of Earnings
In the consolidated financial results for the fiscal year ending December 2025, revenue reached JPY 1,257.9 billion (YoY +7.5%), operating income was JPY 598.8 billion (YoY +10.5%), and net income was JPY 434.0 billion (YoY +12.1%), marking increases in both revenue and profit. Product sales amounted to JPY 1,077.8 billion (YoY +8.0%), with the domestic market at JPY 472.4 billion (YoY +2.5%) and the overseas market at JPY 605.4 billion (YoY +12.8%), reflecting growth in overseas sales. Research and development expenses were JPY 187.6 billion (YoY +3.4%), representing 14.9% of revenue. The operating margin remained high at approximately 47.6%.
Business and Product Trends and Research & Development
Oncology products centered around the cancer domain performed steadily, with increased sales of key products such as Tecentriq and Alecensa. Overseas sales showed significant growth, particularly exports to Roche. Research and development activities remain active, with multiple new indication expansion applications and Phase III trials progressing toward 2026. The dividend policy, including the 100th anniversary commemorative dividend, was also announced, emphasizing shareholder returns.
